CRF Health, a global provider of eCOA solutions for the life sciences industry, has announced that its TrialMax platform has been adopted by a developer of therapeutics for respiratory disease conditions to support one of the largest recorded phase III studies into chronic obstructive pulmonary disease (COPD). The trial, involving more than 19,000 patients, will use the TrialMax platform to deliver electronic versions of key COPD instruments, enabling investigators to monitor exacerbations, while making compliance as easy as possible for patients.
COPD trials routinely face reduced compliance due to a patient population which must regularly complete patient reported outcomes while struggling with lowered energy levels. In this large scale global study, which will involve more than 900 clinical research sites in nearly 40 countries, the TrialMax solution will make data collection as efficient and unobtrusive as possible, driving the collection of a more complete data set through increased compliance.
"Our TrialMax platform is designed to fit into patients' real lives to fuel high compliance, making it the ideal solution to overcome the adherence challenges that are prevalent in COPD trials, especially in a patient population of this size", said John Blakeley, chief business officer at CRF Health. "We're delighted to be part of one of the largest recorded clinical studies of COPD and supporting research advancements that will result in better treatments for those living with the challenges associated with the condition."